Study Summary
This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802 (Circular mRNA encoding Anti-Mesothelin CAR-T) injection in patients with Mesothelin-positive advanced malignant solid tumors.
Want to learn more about this trial?
Request More InfoInterventions
UCMYM802 InjectionBIOLOGICAL
1×10\^8\~2×10\^9 cells will be infused intravenously for 4 times.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Peking University Cancer Hospital & Institute | Beijing | China |